Navigation Links
Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
Date:1/28/2009

ond quarter of fiscal 2008. Net sales of biomaterials products increased 14%, to $13.1 million from $11.5 million in the comparable prior fiscal year period, driven by strong cardiovascular product sales. Cardiovascular sales of $5.3 million, consisting primarily of sales of vascular closure product components to St. Jude Medical, increased 48%, from $3.5 million in the prior fiscal year period. The increase in cardiovascular sales was attributable to ordering patterns of components used in the manufacture of the Angio-Seal(TM) device by St. Jude Medical. Orthopaedic sales were essentially flat year-over-year at $7.1 million versus $7.2 million in the prior fiscal year period, although they were down sequentially from the Company's strong first quarter sales of $8.0 million. Net sales of sports medicine products increased 18% in the second quarter of fiscal 2009 over the prior fiscal year comparable quarter; however, net sales of spine products declined 15% in the same comparable quarter, primarily due to weaker sales of one of the Company's bone void filler products.

The second quarter of fiscal 2009 represented the second full quarter of endovascular product sales to Spectranetics (Nasdaq: SPNC) following the Company's completion of the sale of its endovascular business in May 2008. As previously announced, these sales are at a reduced transfer price compared to the direct to market price reflected in the Company's historical sales figures. As a result of this reduced transfer price, sales of endovascular products during the quarter decreased 47% to $878,000 from $1.7 million in the prior fiscal year period, although overall net unit sales to Spectranetics increased when compared to prior fiscal year and prior sequential quarter end-user unit sales. Sequentially, endovascular product sales increased by 11% in the second quarter, as Spectranetics
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
2. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
3. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
4. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
5. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
6. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
7. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
8. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
9. GEN Reports on Growing Reliance on Microfluidics Technology
10. Novozymes Reports Strong 2008 Results
11. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
(Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
Breaking Biology Technology:Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2
... from Phase II Study Shows 71% Objective Tumor Response Rate ... , - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median ... , ORLANDO, Fla. and TUSTIN, Calif., June 1 Peregrine ... preliminary results from a Phase II trial of its lead ...
... UCB, Inc. and the Crohn,s Disease Working Group (CDWG) today ... Inflammatory Bowel Disease (IBD) for Gastroenterology (GI) Fellows, who each ... or basic research, totaling $175,000 for all four grants. The ... awards were funded by a grant from UCB. A ...
... Therapeutics announced today that promising results from ongoing clinical studies ... presented on AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 ... 2, in Orlando, Florida. , , (Logo: ... , , "We are delighted with the depth ...
Cached Biology Technology:Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6UCB and Crohn's Disease Working Group Award $175,000 in Research Grants to Gastroenterology Fellows 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 4Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 5
(Date:7/10/2014)... Institute for Basic Science (IBS), the main organization of ... Korea, has announced that a group of researchers, led ... technology in the field of optogenetics that can remotely ... new technology "OptoTrk" and it has succeeded with neuronal ... technology is that it requires only light to activate ...
(Date:7/10/2014)... soap might not be ape friendly, and the situation appears ... the Cell Press journal Current Biology on July ... led to the conversion of Southeast Asian forest into oil ... are not put in place very soon, researchers say the ... will be bad news for great apes there as well. ...
(Date:7/10/2014)... Imagine the open ocean as a microbial megacity, teeming ... drop of water, hundreds of types of bacteria can ... of these ocean microbes have their own daily cyclesnot ... to wake up, commute, work, and eat at the ... sun. Light-loving photoautotrophsbacteria that need solar energy to help ...
Breaking Biology News(10 mins):New optogenetic tool for controlling neuronal signalling by blue light 2Hunger for vegetable oil means trouble for Africa's great apes 2New research finds ocean's most abundant organisms have clear daily cycles 2New research finds ocean's most abundant organisms have clear daily cycles 3
... Pop Quiz: what creatures make up more than 70% ... and have long served as model organisms in many ... To begin exploring this question, a new ... was formed and held its inaugural workshop at Nova ...
... are sensitive to social influences but they maintain their ... to what the majority of group members are doing. ... obtain greater rewards, MPI researchers found. ... a rich palette of learning behaviour, both individually and ...
... (UH) Case Medical Center Seidman Cancer Center and Case ... how changes in the genetic composition of breast cancer ... chemotherapy can predict future clinical outcomes in patients. ... reduction in the most commonly mutated genes in breast ...
Cached Biology News:New organization brings together top researchers to sequence genomes of invertebrates 2New organization brings together top researchers to sequence genomes of invertebrates 3Chimpanzees are rational, not conformists 2Deep sequencing of breast cancer tumors to predict clinical outcomes after single dose of therapy 2
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Biology Products: